Candriam Equities L Biotechnology Class I EUR Hedged CapRegister to Unlock Ratings |
Performance History | 28/02/2025 |
Growth of 1,000 (GBP) | Advanced Graph |
![]() | Fund | -8.7 | -0.1 | 2.5 | -3.5 | 2.2 |
![]() | +/-Cat | - | - | - | - | - |
![]() | +/-B’mrk | - | - | - | - | - |
Category: Other Equity | ||||||
Category Benchmark: - |
Key Stats | ||
NAV 13/03/2025 | EUR 2029.87 | |
Day Change | -1.24% | |
Morningstar Category™ | Other Equity | |
ISIN | LU1006082199 | |
Fund Size (Mil) 13/03/2025 | USD 1293.13 | |
Share Class Size (Mil) 13/03/2025 | EUR 14.09 | |
Max Initial Charge | - | |
Ongoing Charge 28/02/2025 | 0.81% |
Investment Objective: Candriam Equities L Biotechnology Class I EUR Hedged Cap |
The objective of the sub-fund is to use discretionary management to benefit from the performance of the market in global equities of companies from the biotechnology sector, and to outperform the benchmark. This sub-fund may be appropriate for investors who wish to achieve this objective over a long investment holding period and who are aware of, understand and are able to bear the specific risks of the sub-fund. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Linden Thomson 29/02/2024 | ||
Servaas Michielssens 30/04/2024 | ||
Inception Date 04/12/2015 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
NASDAQ Biotechnology TR USD | - |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Candriam Equities L Biotechnology Class I EUR Hedged Cap | 31/01/2025 |
|
|
Top 5 Holdings | Sector | % |
![]() | ![]() | 6.27 |
![]() | ![]() | 5.76 |
![]() | ![]() | 5.53 |
![]() | ![]() | 4.98 |
![]() | ![]() | 4.75 |
![]() | ||
![]() ![]() ![]() | ||
Candriam Equities L Biotechnology Class I EUR Hedged Cap |